Moderna’s coronavirus vaccine won’t be ready before late November, CEO says
Moderna CEO Stéphane Bancel has signalled that late November is the earliest that the company could seek Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate, currently in late stage trials. This is based on an arrangement with US regulators that would see an EUA based on two months of safety data from half of the trial participants. The 15,000th participant (out of 30,000) was administered their second dose on September 25, pointing to the late November timeline based on two months of safety data.
Published: October 2, 2020
Fierce PharmaRead Article